^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

CPX-351 IN THERAPHY RELATED ACUTE MYELOID LEUKEMIA AND ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES: A MULTICENTER REAL-LIFE EXPERIENCE IN YOUNG PATIENTS (<60 YEARS OLD)

Published date:
05/12/2021
Excerpt:
One patient showed a partial remission (PR)....The patient in PR, who was FLT3 mutated, underwent reinduction, with administration of CPX-351 in day 1 and 3, obtaining a CR….We found that CPX-351 is active in young patients with t-AML and AML-MRC with a rate of ORR higher than that reported in the pivotal study (63% vs 47%).